Bottom Line: Sacking is a blow to biotechnology
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.CELSIS International's sacking of its chief executive only nine months after the company's flotation is bad news for the nascent biotechnology sector. The risks involved in biotech companies are substantial enough without investors having to worry about management instability.
Tony Martin's former Celsis colleagues are harsh in their judgement. They say Dr Martin turned out to be 'ineffectual' and not up to running the company.
In his defence, Dr Martin was highly regarded by British Bio- technology, his former employer and one of the sector's blue riband stocks.
The least investors might expect of firms asking them for millions of pounds of research finance is that they have a capable and settled chief executive.
Dr Martin joined Celsis only about a year ago, but that still meant he had been at the company longer than both his chairman and his finance director.
Incredibly, Dr Martin's short spell with Celsis has left him with shares worth more than pounds 1.5m, a stake for which he paid only pounds 45,000. This seems an absurdly high reward for his alleged failure.
The Stock Exchange has relaxed its rules to allow young biotech companies, which lack a conventional trading record, to raise money by coming to the market. It would be a pity if this freedom was abused.
Investors in biotech companies have a temptation to ignore pre- flotation jiggling with ownership and capital structures as they focus on the firm's Big Idea. It may pay to be more suspicious.
One of the most disappointing aspects of Dr Martin's sacking is the damage it does to the reputation of Chris Evans, the 'Welsh wizard' behind both Celsis and Chiroscience, another recently listed biotech company.
Dr Evans looked to have great potential as a future stock market star. He has stumbled rather soon.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments